These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 22454102)

  • 21. Expression of immune response biomarkers (PD‑L1, p16, CD3+ and CD8+ TILs) in recurrent head and neck squamous cell carcinoma within previously irradiated areas.
    Pflumio C; Thomas J; Salleron J; Faivre JC; Borel C; Dolivet G; Sastre-Garau X; Geoffrois L
    Oncol Rep; 2021 Mar; 45(3):1273-1283. PubMed ID: 33432367
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma.
    Wang J; Sun H; Zeng Q; Guo XJ; Wang H; Liu HH; Dong ZY
    Sci Rep; 2019 Sep; 9(1):13404. PubMed ID: 31527697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemokine-Cytokine Networks in the Head and Neck Tumor Microenvironment.
    Nisar S; Yousuf P; Masoodi T; Wani NA; Hashem S; Singh M; Sageena G; Mishra D; Kumar R; Haris M; Bhat AA; Macha MA
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective mechanisms of head and neck squamous cell carcinomas from immune assault.
    Young MR
    Head Neck; 2006 May; 28(5):462-70. PubMed ID: 16284974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
    Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
    Front Immunol; 2021; 12():652054. PubMed ID: 34305889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The immune system and head and neck squamous cell carcinoma: from carcinogenesis to new therapeutic opportunities.
    Freiser ME; Serafini P; Weed DT
    Immunol Res; 2013 Dec; 57(1-3):52-69. PubMed ID: 24218361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PDGF-AA mediates mesenchymal stromal cell chemotaxis to the head and neck squamous cell carcinoma tumor microenvironment.
    Watts TL; Cui R; Szaniszlo P; Resto VA; Powell DW; Pinchuk IV
    J Transl Med; 2016 Dec; 14(1):337. PubMed ID: 27931212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunosuppressive effects of soluble factors secreted by head and neck squamous cell carcinoma on dendritic cells and T lymphocytes.
    Kacani L; Wurm M; Schennach H; Braun I; Andrle J; Sprinzl GM
    Oral Oncol; 2003 Oct; 39(7):672-9. PubMed ID: 12907206
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The promise of immunotherapy in head and neck squamous cell carcinoma.
    Economopoulou P; Agelaki S; Perisanidis C; Giotakis EI; Psyrri A
    Ann Oncol; 2016 Sep; 27(9):1675-85. PubMed ID: 27380958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioimmunotherapy of experimental head and neck squamous cell carcinoma (HNSCC) with E6-specific antibody using a novel HPV-16 positive HNSCC cell line.
    Harris M; Wang XG; Jiang Z; Goldberg GL; Casadevall A; Dadachova E
    Head Neck Oncol; 2011 Feb; 3(1):9. PubMed ID: 21314983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy.
    Bhat AA; Yousuf P; Wani NA; Rizwan A; Chauhan SS; Siddiqi MA; Bedognetti D; El-Rifai W; Frenneaux MP; Batra SK; Haris M; Macha MA
    Signal Transduct Target Ther; 2021 Jan; 6(1):12. PubMed ID: 33436555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma.
    Sun W; Li WJ; Wei FQ; Wong TS; Lei WB; Zhu XL; Li J; Wen WP
    Oncotarget; 2016 Jun; 7(25):37714-37727. PubMed ID: 27177223
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer.
    Heusinkveld M; Goedemans R; Briet RJ; Gelderblom H; Nortier JW; Gorter A; Smit VT; Langeveld AP; Jansen JC; van der Burg SH
    Int J Cancer; 2012 Jul; 131(2):E74-85. PubMed ID: 22020783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment.
    Li ZX; Zheng ZQ; Wei ZH; Zhang LL; Li F; Lin L; Liu RQ; Huang XD; Lv JW; Chen FP; He XJ; Guan JL; Kou J; Ma J; Zhou GQ; Sun Y
    Theranostics; 2019; 9(25):7648-7665. PubMed ID: 31695792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting the immune system: novel therapeutic approaches in squamous cell carcinoma of the head and neck.
    Hoffmann TK; Bier H; Whiteside TL
    Cancer Immunol Immunother; 2004 Dec; 53(12):1055-67. PubMed ID: 15095020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunology and Immunotherapy of Head and Neck Cancer.
    Ferris RL
    J Clin Oncol; 2015 Oct; 33(29):3293-304. PubMed ID: 26351330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy for head and neck cancer patients: shifting the balance.
    Turksma AW; Braakhuis BJ; Bloemena E; Meijer CJ; Leemans CR; Hooijberg E
    Immunotherapy; 2013 Jan; 5(1):49-61. PubMed ID: 23256798
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis.
    Chen X; Yan B; Lou H; Shen Z; Tong F; Zhai A; Wei L; Zhang F
    Mol Immunol; 2018 Apr; 96():28-36. PubMed ID: 29477933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impaired T lymphocyte function increases tumorigenicity and decreases tumor latency in a mouse model of head and neck cancer.
    Ku TK; Crowe DL
    Int J Oncol; 2009 Nov; 35(5):1211-21. PubMed ID: 19787277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.